Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Tazarotene gel may be more effective for acne than adapalene gel.

Dutasteride is more effective than finasteride for treating BPH without extra safety risks.

Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

Method can accurately measure five BPH drugs at once.

Using finasteride with TIP extends time off period for prostate cancer patients.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.

Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.

A method was created in 2012 to accurately and precisely measure tamsulosin and finasteride in medicine using second derivative spectrophotometric method.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

TA-Ado effectively promotes hair growth and reduces hair loss.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.